Gilead Just Spent $2 Billion on a Cancer Weapon… for Autoimmune Disease

The traditional approach has been to suppress the entire immune system, like shutting off all the lights in a building to stop one flickering bulb. It works, sort of, but the side effects are brutal.

OM336 takes a different approach. It targets BCMA (B-cell maturation antigen), a protein found on the surface of mature B cells and plasma cells, the very cells producing those harmful antibodies. By bridging these cells to T cells via CD3, OM336 essentially commands the immune system to destroy its own malfunctioning troops. The goal is a "reset": wipe out the bad actors, let healthy B cells grow back, and achieve lasting remission without chronic immunosuppression.

It's the same basic technology that's already approved for blood cancers like multiple myeloma. Gilead is betting it can work just as well when the enemy isn't a tumor, but your own confused immune system.

The Galapagos Twist

This isn't a straightforward buyout. Gilead structured the deal with an unusual wrinkle involving Galapagos, its longtime Belgian biotech partner. Under the arrangement, Galapagos would fund 50% of both the upfront and milestone payments to Ouro's shareholders. In return, Galapagos absorbs Ouro's operating assets and employees, and covers OM336's development costs through registrational studies (expected around 2027).

After that, costs get split equally. Gilead keeps global commercialization rights (except Greater China, which belongs to Keymed Biosciences) and pays Galapagos royalties of 20% to 23% on net sales.

Translation: Gilead gets the commercial upside while splitting the development risk. It's like co-signing a mortgage but keeping the house. For Galapagos, it's a chance to run meaningful clinical programs and earn royalties on a potentially huge asset. Both sides have skin in the game, and both need OM336 to work.

What the Data Shows (and Doesn't)

Let's be honest about what we know. OM336 has FDA Fast Track and Orphan Drug designations, which means the agency thinks the drug addresses serious unmet needs and is willing to expedite its review. More than 80 patients have been dosed across autoimmune and oncology studies.

The company points to case reports published in the New England Journal of Medicine showing rapid lab normalization and remissions lasting six months or longer in patients with autoimmune hemolytic anemia (AIHA), a condition where the body destroys its own red blood cells. Ouro is also running trials in Sjögren's disease and idiopathic inflammatory myopathy.

But here's the catch: no formal clinical trial results have been published yet. Interim data is expected sometime in 2026. That means Gilead is writing a $1.675 billion check based largely on early signals, mechanism-of-action logic, and conviction that the autoimmune T-cell engager wave is real.

Gilead's Bigger Bet

This acquisition makes more sense when you zoom out. Gilead has been loudly telegraphing its intention to diversify beyond HIV, which still dominates its revenue. The company has over 50 active clinical programs, the most diverse lineup in its history.

The Ouro deal slots neatly into that strategy. Gilead already has oncology assets from its $21 billion Immunomedics acquisition in 2020 and the Jounce Therapeutics partnership. Adding an autoimmune T-cell engager fills a gap in the immunology column, and it positions Gilead at the leading edge of a trend that's rapidly gaining momentum.

Across the industry, bispecific antibodies are migrating from cancer wards to rheumatology clinics. The logic is simple: if you can precisely eliminate the cells causing disease, why wouldn't you try it everywhere those cells are the problem?

The Bottom Line

Gilead paid a premium price for a very early-stage asset. The $2.175 billion total makes this one of the largest acquisitions of a pre-revenue, pre-data company in recent memory. The risk-sharing deal with Galapagos softens the blow, but the fundamental bet remains: can T-cell engagers, born in oncology, deliver the same kind of transformative results in autoimmune disease?

If the data cooperates, Gilead could be sitting on a franchise-defining platform. If it doesn't, this becomes an expensive lesson in paying top dollar for potential.

Either way, the message to the rest of biotech is clear. The autoimmune gold rush is on, and the price of admission just went way up.

Genmab Paid $1.8 Billion for Three Cancer Drugs. Two Are Already Dead.

Genmab dropped $1.8 billion on ProfoundBio's cancer drug pipeline in 2024. Less than two years later, two of the three clinical-stage assets are dead and a third is barely enrolling patients. Now the entire deal rides on one surviving drug.